Article| Volume 79, ISSUE 7, P855-862, July 1998

Download started.


Analysis of health-related quality of life and muscle impairment in individuals with amyotrophic lateral sclerosis using the medical outcome survey and the tufts quantitative neuromuscular exam

      This paper is only available as a PDF. To read, Please Download here.


      Objective: The Tufts Quantitative Neuromuscular Exam (TQNE) is commonly used to assess the rate of disease progression in individuals with amyotrophic lateral sclerosis (ALS). The Medical Outcome Study Short Form (SF-36) is a general method to assess health-related quality of life (HRQL). This study examined the relationship between the TQNE and SF-36, established the reliability and responsiveness of each, and contrasted the HRQL between individuals with ALS and the general population.
      Design: Subjects (31) completed the SF-36 and TQNE within 1 week to determine reliability. Subjects (17) also completed both the TQNE and SF-36 each month for 1 year after diagnosis of ALS to establish the relationship between the two assessment tools.
      Setting: A primary care university teaching hospital.
      Patients: Thirty-one subjects with an age range of 27 to 76 years (mean 59.1, SD 10.32), recently diagnosed with ALS.
      Results: Each test was highly reliable and responsive. The intraclass correlations (2, 1) were consistently higher for the TQNE (.93 to .98) than for the SF-36 (.57 to .90). Changes in physical function were correlated to changes in lower extremity force megascores (.48).
      Conclusion: Both the TQNE and the SF-36 are reliable and responsive and appear important in characterization of patient status after ALS is diagnosed.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Archives of Physical Medicine and Rehabilitation
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Haverkamp LJ
        • Appel V
        • Appel SH
        Natural history of amyotrophic lateral sclerosis in a database population.
        Brain. 1995; 118: 707-719
        • McDonald ER
        • Wiedenfeld SA
        • Hillel A
        • Carpenter CL
        • Walker RA
        Survival in amyotrophic lateral sclerosis.
        in: The role of psychological factors. 2nd ed. Arch Neurol. 51. 1994: 17-23
        • Hunter MD
        • Robinson IC
        • Neilson S
        The functional and psychological status of patients with amyotrophic lateral sclerosis: some implications for rehabilitation.
        Disabil Rehabil. 1993; 15: 119-126
        • Norris FH
        • Calanchini PR
        • Fallat RJ
        • Panchari S
        • Jewett B
        The administration of guanidine in amyotrophic lateral sclerosis.
        Neurology. 1974; 244: 721-728
        • Olarte MR
        Therapeutic trials in amyotrophic lateral sclerosis.
        Adv Neurol. 1982; : 555-557
        • Andres PL
        • Hedlund W
        • Finison L
        • Conlon T
        • Felmus M
        • Munsat TL
        Quantitative motor assessment in amyotrophic lateral sclerosis.
        Neurology. 1986; 36: 937-941
        • Appel V
        • Stewart SS
        • Smith G
        • Appel SH
        A rating scale for amyotrophic lateral sclerosis: description and preliminary experience.
        Ann Neurol. 1987; 22: 328-333
        • Eisen A
        • Schulzer M
        • MacNeil M
        • Pant B
        • Mak E
        Duration of amyotrophic lateral sclerosis is age dependent.
        Muscle Nerve. 1993; 16: 27-32
        • Pradas J
        • Finison L
        • Andres PL
        • Thornell B
        • Hollander D
        • Munsat TL
        The natural history of amyotrophic lateral sclerosis and the use of natural history controls in therapeutic trials.
        Neurology. 1993; 43: 751-755
        • Munsat TL
        • Andres PL
        • Finison L
        • Conlon T
        • Thibodeau L
        The natural history of motoneuron loss in amyotrophic lateral sclerosis.
        Neurology. 1988; 38: 409-431
        • Bensimon G
        • Lacombley L
        • Meininger V
        A controlled trial of Riluzole in amyotrophic lateral sclerosis.
        N Engl J Med. 1994; 330: 585-591
        • Bocker FM
        • Seibold I
        • Neundorfer B
        Physical disability and depression in patients with advanced amyotrophic lateral sclerosis (ALS).
        Fortsch Neurol Psychiatr. 1990; 58: 224-236
        • Rubenstein LV
        • Calkins DR
        • Greenfield S
        • Jette AM
        • Meenan RF
        • Nevins MA
        • et al.
        Health status assessment for elderly patients: report of the Society of General Internal Medicine Task Force on Health Assessment.
        J Am Geriatr Soc. 1988; 37: 562-569
        • Ware JE
        • Snow KK
        • Kosinski M
        • Gandek B
        SF-36 health survey manual and interpretation guide.
        The Health Institute, New England Medical Center, Boston (MA)1993
        • Stewart AL
        • Greenfield S
        • Hays RD
        • Wells K
        • Rogers WH
        • Berry SD
        • et al.
        Functional status and well being of patients with chronic conditions.
        JAMA. 1989; 262: 907-913
        • McHorney CA
        • Ware JE
        • Rogers W
        • Raczek AE
        • Lu JF
        The validity and relative precision of MOS short- and long-form health status scales and Dartmouth COOP charts.
        Med Care. 1992; 30: MS253-MS265
        • McHorney CA
        • Ware JE
        • Raczek AE
        The MOS 36-item short-form health survey (SF-36): II: psychometric and clinical tests of validity in measuring physical and mental health constructs.
        Med Care. 1993; 31: 247-263
        • McHorney CA
        • Ware JE
        • Rachel Lu JF
        • Sherbourne CD
        The MOS 36-item short form health survey (SF-36): III: tests of data quality, scaling assumptions, and reliability across diverse patient groups.
        Med Care. 1994; 32: 40-66
        • Enloe LJ
        • Shields RK
        Evaluation of health related quality of life in individuals with vestibular disease using a disease specific and general outcome measure.
        Phys Ther. 1997; 77: 890-903
        • Ruhland JL
        • Shields RK
        The efficacy of a home exercise program on impairment and health related quality of life in persons with chronic peripheral neuropathy.
        Phys Ther. 1997; 77: 1021-1024
        • Shields RK
        • Ruhland JL
        • Ross M
        A descriptive study of patients with amyotrophic lateral sclerosis (ALS) using the Tufts Quantitative Neuromuscular Exam (TQNE) and the Medical Outcomes Study Short Form Health Survey (SF-36).
        Phys Ther. 1996; 76 ([abstract]) (Suppl): S32
        • World Federation of Neurology Research Committee on Neuromuscular Disease
        Classification of neuromuscular diseases.
        J Neurol Sci. 1988; 86: 333-360
        • Andres PL
        • Finison LJ
        • Conlon T
        • Thibodeau LM
        • Munsat TL
        Use of composite scores (megascores) to measure deficit in amyotrofic lateral sclerosis.
        Neurology. 1988; 38: 405-408
        • Bradley WG
        • Hedlund W
        • Cooper C
        • Desousa GJ
        • Gabbai A
        • Mora JS
        • et al.
        A double-blind controlled trial of bovine brain gangliosides (cronassial).
        Neurology. 1984; 34: 1079-1082
        • Smith RA
        • Melmed S
        • Sherman B
        • Frane J
        • Munsat TL
        • Festoff BW
        Recombinant growth hormone treatment of amyolateral sclerosis.
        Muscle Nerve. 1993; 16: 624-633
        • Keleman J
        • Hedlund W
        • Murray-Douglas P
        • Munsat TL
        Lecithin is not effective in amyotrophic lateral sclerosis.
        Neurology. 1982; 32: 315-316
        • Munsat TL
        • Easterday CS
        • Levy S
        • Wolff SM
        • Hiatt R
        Amantadine and quanedine are ineffective in ALS.
        Neurology. 1981; 31: 1054-1055
        • Munsat TL
        • Taft J
        • Kasdon D
        Intrathecal infusion of thyrotropinreleasing hormone (TRH) in amyotrophic lateral sclerosis.
        Neurol Clin. 1987; 5: 159-170
        • Festoff RA
        • Smith S
        • Melmed J
        • Franc B
        • Sherman B
        • Finson R
        • et al.
        Tufts Quantitative Neuromuscular Examination and amyotrophic lateral sclerosis trials in the recombinant age.
        Ann Neurol. 1988; 24: 138-139
        • Munsat TL
        • Taft J
        • Jackson IM
        • Andres PL
        • Hollander D
        • Skerry L
        • et al.
        Intrathecal thyrotropin releasing hormone does not alter the progressive course of ALS: experience with an intrathecal drug delivery system.
        Neurology. 1992; 42: 1049-1056
        • Shrout PE
        • Fleiss JL
        Intraclass correlation: uses in assessing rate reliability.
        Psychol Bull. 1979; 86: 420-428
        • Guyatt G
        • Walter S
        • Norman G
        Measuring change over time: assessing the usefulness of evaluative instruments.
        J Chron Dis. 1987; 40: 171-178
        • Lachin JM
        Introduction to sample size determination and power analysis for clinical trials.
        Control Clin Trials. 1981; 2: 93-113
        • Jette DU
        • Downing J
        Health status of individuals entering a cardiac rehabilitation program as measured by the Medical Outcomes Study 36-Item Short Form Survey (SF-36).
        Phys Ther. 1994; 74: 521-527